Generic Medicine Info
Should be taken with food. Take w/ or immediately after meals.
Hypersensitivity. Acute porphyria, G6PD deficiency, infants <1 month. Pregnancy at term (during labour and delivery). Severe renal impairment, anuria, oliguria, significantly elevated serum creatinine, CrCl <60 ml/min or eGFR <45 mL/min, history of cholestatic jaundice or hepatic impairment associated with previous nitrofurantoin use. Concurrent vaccination with live polio vaccines.
Special Precautions
Patient with anaemia, diabetes mellitus, vitamin B deficiency, electrolyte imbalance, debilitating diseases, pre-existing pulmonary diseases, neurological disorders, or allergic diathesis. Lactation. Children and elderly. Patient Counselling This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery. This drug may cause yellow or brown discoloration of urine. Monitoring Parameters Monitor CBC; LFT and renal function periodically. Monitor for pulmonary reactions (e.g. malaise, dyspnoea, cough, fever, and radiologic evidence of diffuse interstitial pneumonitis or fibrosis), and signs of numbness or tingling of extremities.
Adverse Reactions
Significant: Optic neuritis, peripheral neuropathy, superinfection, C. difficile-associated diarrhoea, haemolytic anaemia. Blood and lymphatic system disorders: Agranulocytosis, aplastic anaemia. Cardiac disorders: Angina. Eye disorders: Amblyopia. Gastrointestinal disorders: Diarrhea, dyspepsia, abdominal pain, constipation, emesis. General disorders and administration site conditions: Fever, chills, malaise, asthenia. Immune system disorders: Anaphylactoid reactions, angioedema, urticaria. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Arthralgia. Nervous system disorders: Dizziness, drowsiness. Respiratory, thoracic and mediastinal disorders: Acute pulmonary hypersensitivity reactions. Skin and subcutaneous tissue disorders: Pruritus, alopecia.
Potentially Fatal: Rarely, cholestatic jaundice, hepatitis, hepatic necrosis. Acute, subacute or chronic pulmonary toxicity, peripheral neuropathy.
B contraindicated at 38-42 weeks gestation
Drug Interactions
Reduced rate and extent of absorption with antacids containing Mg trisilicate. Increased serum level and toxicity and decreased renal excretion with uricosuric drugs (e.g. probenecid, sulfinpyrazone). Antagonistic effects with quinolone antibacterials. Decreased antimicrobial effect with effects with carbonic anhydrase inhibitors (e.g. acetazolamide). May diminish the therapeutic effect of norfloxacin, and live polio vaccine.
CIMS Class
Other Antibiotics
ATC Classification
J01XE01 - nitrofurantoin ; Belongs to the class of nitrofuran derivative antibacterials. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on nitrofurantoin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in